FDA approves Pfizer’s eczema treatment Eucrisa

SILVER SPRING, Md. — The Food and Drug Administration on Wednesday announced its approval of Pfizer’s Eucrisa (crisaborole). The ointment is indicated to treat mild to moderate eczema in patients two years of age and older. 

 

“The approval of Eucrisa is great news for the children and adults suffering from mild to moderate eczema, a community that has not had a new prescription treatment for more than 10 years,” Pfizer Innovative Health group president Albert Bourla said. “This is also an important milestone for Pfizer as we continue to build on our heritage in Inflammation and Immunology by offering innovative treatment options to patients who need them.”

 

“Today’s approval provides another treatment option for patients dealing with mild to moderate atopic dermatitis,” said Amy Egan, deputy director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research.

 

The drug was brought into Pfizer’s portfolio in May with its $5.2 billion acquisition of Anacor Pharmaceuticals. In May, the company said that it projected Eucrisa to potentially bring in $2 billion or more once it received approval.